ClinicalTrials.gg
CompletedNCT03765944Updated Feb 25, 2019

Bioequivalence Study of NPC-12 (Sirolimus) Granules and Tablets

A Phase 1 interventional study of sirolimus in Bioequivalence Study, sponsored by Nobelpharma. Completed at 1 site in Japan. Open to participants aged 20 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-25.

Sponsored by Nobelpharma · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
20 Years to 39 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the bioequivalece of NPC-12 granules in compare with NPC-12T tablets in Japanese healthy Adults

02

Conditions studied

  • Bioequivalence Study
03

In context

Lead sponsor

Nobelpharma is the lead sponsor of 34 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 39 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Japanese healthy subjects aged 20 to 39 years of age
  2. Subjects with ≥ 18.5 kg/m2 and \< 25.0 kg/m2
  3. Subjects who are considered by the investigator as suitable for participation in the trial from lab test results at screening
  4. Subjects who are considered by the investigator as suitable for participation in the trial from lab test results on the day before administration
  5. Subjects who write
  6. Subjects who are able to comply with the study requirements during the study period

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have a history of to sirolimus or sirolimus derivative
  2. Subjects who have a history of hypersensitivity or allergies to other drug
  3. SUbjects who have an acute or chronic infectious diseases
  4. Subjects who have a current or a history of disease which is considered inappropriate to be involved in the study, or who has any current disease to require treatments
  5. Subjects who have diagnosed with alcoholism or a history of alcoholism
  6. Subjects who have an abnormal findings (pneumonia, etc) from the result of chest CT at screening
  7. Subjects who have been administered other drug within 12 weeks before the initial administration
  8. Subjects who have performed blood collection or donation as follows

    • Collected or donated 200 ml or more whole blood within 4 weeks before the initial administration
    • Male subject; collected or donated more than 400 mL whole blood within 12 weeks before the initial administration
    • Female subjects; collected or donated more than 400 mL whole blood within 16 weeks before the initial administration
    • Collected or donated blood component within 2 weeks before the initial administration
  9. Subjects who have positive results for HBs antigen, HBs antibody, HBc antibody, antibody, antigen/antibody, or syphilis
  10. Subjects who received any non-prescription or prescription drug within 12 weeks before the initial administration
  11. Subjects who are pregnant/lactating, or do not agree to during the period from the screening until 8 weeks after the final administration due to planning to become pregnant
  12. Subjects who cannot speak, read and write in Japanese
  13. Subjects who are considered by the investigator as unsuitable for participation in the trial
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Active comparator
    NPC-12 granule

    NPC-12 granules (1.0g: 2mg sirolimus)

    Drug: sirolimus

  • Active comparator
    NPC-12T tablet

    NPC-12T 2 tablets (2mg sirolimus)

    Drug: sirolimus

Interventions

  • SIngle administration under fasted condition

06

What researchers measure

Primary outcomes

  1. Blood sirolimus concentration

    Whole blood concentration of sirolimus will be measured and compared between NPC-12 granules and NPC-12T tablets.

    Time frame: Pre-dose and post-dose (0.5, 1, 1.5, 2, 4, 8, 12, 18, 24, 48 and 72 hours)

07

Study locations

1 site
  • Clinique Soigner
    Matsudo, Chiba 270 -2231, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Dec 2018, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2018
First posted
Dec 5, 2018
StartActual
Dec 5, 2018
Primary completionActual
Dec 29, 2018
CompletionActual
Dec 29, 2018
Last update
Feb 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03765944
Lead sponsor
Nobelpharma
Responsible party
Sponsor
First posted
Dec 5, 2018
Start date
Dec 5, 2018
Primary completion
Dec 29, 2018
Completion
Dec 29, 2018
Last update
Feb 25, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion